BPC-157 is shown acting on the gut to repair the mucosal barrier and reduce inflammation
The medication (morphine (16 mg/kg s.c.), the tested agents (gastric pentadecapeptide BPC 157 (10 pg, 10 ng and 10 g/kg i.p.), naloxone (10 mg/kg s.c.), haloperidol (1 mg/kg i.p.) or saline (5 ml/kg i.p.) was given accordingly at either 30 min, 20 min or 10 min before the first assessment (time "0"), and subsequently, the mice were assessed at 15, 30, 45, 60, 90, 120, 150 and 180 min intervals (time "+")
Two independent investigators systematically searched Web of Science, PubMed, and Cochrane Library and extracted data from 87 studies with 4928 ASD children and 4181 healthy control (HC) children
Causes of Refractory Reflux Symptoms in Patients Receiving Proton Pump Inhibitor Therapy Incorrect initial diagnosis Nonreflux esophagitispill injury, skin diseases, eosinophilic esophagitis, infection Heart disease Chest wall pain Gastric pain Additional diagnoses Dyspepsia Delayed gastric emptying Gastritis Peptic ulcer disease Nonulcer dyspepsia Inadequate acid suppression Noncompliance Rapid metabolizers of proton pump inhibitors Dose timing Insufficient dose Zollinger-Ellison syndrome Nonacid reflux Adenocarcinoma in Barrett esophagus Postoperative reflux Partial gastrectomy Vertical-banded gastroplasty Esophageal dysmotility Spasm Achalasia Nutcracker esophagus Functional chest pain Hypersensitive esophagus Somatic features of depression Functional heartburn Free regurgitation Absence of lower esophageal sphincter tone Large hiatal hernia Achalasia Rumination rumination or gastroparesis) or functional conditions (eg, functional heartburn)
